Cas No.: | 38819-10-2 |
Chemical Name: | 9-beta-d-Arabinofuranosylguanine |
Synonyms: | 6H-Purin-6-one,2-amino-9-b-D-arabinofuranosyl-1,9-dihydro-;2-AMino-9-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxyMethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one;9-beta-D-Arabinofuranosylguanine Hydrate;Arabinoguanosine;Araguanosine;ara-Guanosine;Guanine arabinoside;-D-Arabinofuranosylguanine Hydrate;9-β9-beta-Arabinosylguanine;9-(Beta-D-Arabinofuranosyl)Guanine;9-B-D-ARABINOFURANOSYLGUANINE;9-Beta-D-Arabinofuranosylguanine;Ara-G;-D<;9-arabinofuranosylguanine;9-β-D-Arabinofuranosylguanine Hydrate;ARABINOFURANOSYL-GUANINE;Arabinosylguanine;GUANINE-9-ARABINOSIDE;Ara-G Hydrate;Guanine 9-β-D-Arabinofuranoside Hydrate;NSC 76352;9-(b-d-arabinofuranosyl)guanine;0Z99WX0GPF;Guanine, 9-(beta-D-arabinofuranosyl)-;9-(BETA-D-ARABINOFURANOSYL)-GUANINE;6H-P;6H-Purin-6-one, 2-amino-9-beta-D-arabinofuranosyl-1,9-dihydro-;C10H13N5O5;2-amino-9-(beta-D-arabinofuranosyl)-1,9-dihydro-6H-purin-6-one;2-Amino |
SMILES: | O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@@]([H])([C@]1([H])N1C([H])=NC2C(N([H])C(N([H])[H])=NC1=2)=O)O[H])O[H] |
Formula: | C10N5O5H13 |
M.Wt: | 283.2407 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Ara-G (9-β-D-Arabinofuranosyl guanine) is an inducer of apoptosis, inhibitor of DNA synthesis, an antimetabolite, and antineoplastic. Ara-G is converted by cellular kinases to the active 5'-triphosphate, Ara-GTP. Incorporation of Ara-GTP into DNA leads to inhibition of DNA synthesis and apoptosis. The cellular accumulation of Ara-GTP is indicative of the clinical response to treatment with nelarabine, the prodrug. The differential accumulation and consequent selective cytotoxicity of Ara-G in T cells has been postulated to be due to the higher accumulation and slower elimination of ara-GTP in these cells. Nelarabine was developed because of poor water solubility of Ara-G, but Ara-G is DMSO-soluble. Nelarabine is approved in the United States for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). |